drugset / Trial / NCT00525096

Exemestane + Celecoxib vs Exemestane + Placebo in Metastatic Breast Cancer

NCT00525096

Phase 3 Completed 157 enrolled ARCAGY/ GINECO GROUP
RandomizedParallel-groupDouble-blindTreatment

Summary

To discover if the adding of a coxib increases the efficacy of the Aromasine.

Timeline

Start
2003-07
Primary completion
2004-12
Completion
2004-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Celecoxib Other / unclassified 400 mg Oral
Background Exemestane Small molecule 25 mg Oral

Indications